Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma.
Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, Falini B, Gobbi M, Gentilini P, Lauta VM, Bendandi M, Gherlinzoni F, Magagnoli M, Venturi S, Aitini E, Tabanelli M, Leone G, Liso V, Tura S. Zinzani PL, et al. Among authors: liso v. Blood. 1997 Jun 1;89(11):3974-9. Blood. 1997. PMID: 9166835 Free article. Clinical Trial.
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.
Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G; GIMEMA CML Working Party. Castagnetti F, et al. Blood. 2009 Apr 9;113(15):3428-34. doi: 10.1182/blood-2007-08-103499. Epub 2009 Feb 11. Blood. 2009. PMID: 19211938 Free article. Clinical Trial.
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G, Bernasconi P, Boni M, Castoldi GL, Ciolli S, Clavio M, Cox MC, Cuneo A, Del Poeta G, Dini D, Falzetti D, Fanin R, Gobbi M, Isidori A, Leoni F, Liso V, Malagola M, Martinelli G, Mecucci C, Piccaluga PP, Petti MC, Rondelli R, Russo D, Sessarego M, Specchia G, Testoni N, Torelli G, Mandelli F, Tura S. Visani G, et al. Among authors: liso v. Leukemia. 2001 Jun;15(6):903-9. doi: 10.1038/sj.leu.2402142. Leukemia. 2001. PMID: 11417475 Review.
Therapy of acute myelogenous leukemia in adults.
Petti MC, Broccia G, Caronia F, Di Raimondo F, Fioritoni G, Ladogana S, Leone G, Liso V, Musso M, Neri A, et al. Petti MC, et al. Among authors: liso v. Haematol Blood Transfus. 1990;33:249-53. doi: 10.1007/978-3-642-74643-7_45. Haematol Blood Transfus. 1990. PMID: 2182417 Clinical Trial. No abstract available.
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.
Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Ladetto M, et al. Blood. 2008 Apr 15;111(8):4004-13. doi: 10.1182/blood-2007-10-116749. Epub 2008 Jan 31. Blood. 2008. PMID: 18239086 Free article. Clinical Trial.
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up.
Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M, Cantore N, Di Bona E, Ferrara F, Fioritoni G, Gallo E, Invernizzi R, Lazzarino M, Liso V, Mariani G, Ricciuti F, Selleri C, Sica S, Veneri D, Mandelli F; GIMEMA (Gruppo Italiano Malattie Ematologische dell'Adulto) Italian Cooperative Group. Avvisati G, et al. Among authors: liso v. Blood. 2002 Nov 1;100(9):3141-6. doi: 10.1182/blood-2002-02-0352. Blood. 2002. PMID: 12384411 Free article. Clinical Trial.
Consensus conference on the management of tumor lysis syndrome.
Tosi P, Barosi G, Lazzaro C, Liso V, Marchetti M, Morra E, Pession A, Rosti G, Santoro A, Zinzani PL, Tura S. Tosi P, et al. Among authors: liso v. Haematologica. 2008 Dec;93(12):1877-85. doi: 10.3324/haematol.13290. Epub 2008 Oct 6. Haematologica. 2008. PMID: 18838473 Free article.
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.
Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, De Rosa G, Belhabri A, Giustolisi R, Delarue R, Liso V, Mirto S, Leone G, Bourhis JH, Fioritoni G, Jehn U, Amadori S, Fazi P, Hagemeijer A, Willemze R; EORTC and GIMEMA Leukemia Groups. Suciu S, et al. Among authors: liso v. Blood. 2003 Aug 15;102(4):1232-40. doi: 10.1182/blood-2002-12-3714. Epub 2003 Apr 24. Blood. 2003. PMID: 12714526 Free article. Clinical Trial.
SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia.
Mauro FR, Bandini G, Barosi G, Billio A, Brugiatelli M, Cuneo A, Lauria F, Liso V, Marchetti M, Meloni G, Montillo M, Zinzani P, Tura S; Italian Society of Hematology; Società Italiana di Ematologia Sperimentale; Gruppo Italiano Trapianto di Midollo Osseo. Mauro FR, et al. Among authors: liso v. Leuk Res. 2012 Apr;36(4):459-66. doi: 10.1016/j.leukres.2011.08.013. Epub 2011 Sep 1. Leuk Res. 2012. PMID: 21885123
233 results